XY0VX83
Introduction Vein Graft to New Technology Group 3 with Endothelial Damage Inhibitor, External Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | Y Extracorporeal |
| Operation | 0 Introduction |
| Body Part | V Vein Graft |
| Approach | X External |
| Device | 8 Endothelial Damage Inhibitor |
| Qualifier | 3 New Technology Group 3 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers Introduction procedures performed on blood or another substance outside the body, where a therapeutic, diagnostic, nutritional, physiological, or prophylactic agent is put into that extracorporeal circuit rather than directly into the patient. In practice, this often means treating blood as it passes through an external device - for example, exposing it to a filtering, adsorption, or light-based therapy - before it's returned to the body, or introducing an agent into another extracorporeal system such as a perfusion or dialysis circuit.
This approach is used when a substance needs to interact with blood or another body fluid in a controlled external environment, often to remove harmful compounds, deliver a treatment more precisely, or support a patient during critical illness. Because it sits in New Technology, the specific substance or delivery method reflects a recently approved product or technique.
Anatomy & Axis Detail
Vein Graft
This code captures introduction of a new-technology substance directly into a vein graft, the surgically harvested or synthetic conduit used to bypass a diseased native vessel, most often in coronary or peripheral arterial bypass surgery. Vein grafts, commonly derived from the saphenous vein, are vulnerable to early thrombosis, intimal hyperplasia, and graft failure, so introducing an agent such as a novel anticoagulant, antiproliferative, or preservation solution into the graft itself is intended to improve patency or protect the conduit at the time of implantation. Because the target is the graft conduit rather than the native vasculature it is anastomosed to, documentation must clearly indicate that the substance was delivered into the graft segment, distinguishing this from introduction into a native vein or artery elsewhere in the same operative episode.
Approach: External
External approach in New Technology applies to procedures performed directly on the skin, mucous membranes, or via direct visualization without penetrating a body cavity, such as applying or activating a device against the body surface. It contrasts with Percutaneous approaches, which require instrument entry through the skin rather than surface-level contact.
Device / Substance / Technology: Endothelial Damage Inhibitor
This value identifies a substance administered to inhibit damage to the vascular endothelium, most often used during procedures involving extracorporeal circulation such as cardiopulmonary bypass or ECMO, where shear stress and inflammatory activation can injure vessel lining. It functions as a protective agent rather than an anticoagulant, distinguishing it from the anticoagulant and anti-infective substances described elsewhere in this axis.
Qualifier: New Technology Group 3
Group 3 identifies the cohort of technologies added to this section for the 2017-2018 fiscal year, following shortly after the section's initial 2016 rollout. It functions purely as a chronological tag rather than a clinical descriptor, meaning the actual device or agent must be read from the rest of the code. It is easily confused with Group 2 and Group 4, which flank it in sequence.
Coding & Documentation
Coding requires documentation that identifies the specific substance introduced, confirms it was introduced into an extracorporeal circuit rather than directly into the patient's body, and names the approved New Technology product used to deliver it. The record should also make clear the intent - therapeutic, diagnostic, nutritional, or prophylactic - since that shapes which specific code applies.
A common mistake is coding this as a standard Administration or Introduction procedure from another PCS section when the substance and device actually match an approved New Technology entry, or missing the extracorporeal element and coding it as if the substance were introduced directly into the bloodstream. Coders should also watch for cases where the extracorporeal treatment is bundled into a larger procedure, such as an extracorporeal support circuit, and needs to be coded separately.
Commonly Confused With
This family is frequently confused with standard Administration section codes for introducing substances into the body, and with extracorporeal Assistance or Performance procedures that support a physiological function rather than deliver a substance. The distinguishing feature is that this code captures the act of introducing a substance into an external circuit or fluid, not the act of supporting or replacing an organ function.